Cord Blood Banking: Myths vs. Reality

FACT accreditation ensures stem cell banks meet strict quality and safety standards for cellular therapy. It’s a certification from the Foundation for the Accreditation of Cellular Therapy (FACT), a nonprofit organization that evaluates medical and laboratory practices globally. FACT standards cover every aspect of stem cell banking, from collection and processing to storage and release, ensuring these hematopoietic and mesenchymal stem cells are prepared for medical use.

Key points to know:

• FACT Standards: Focus on clinical use and rigorous quality controls, ensuring safety and reliability.
• Global Reach: 339 organizations worldwide are FACT-accredited as of May 2026.
• Specific Standards: Includes FACT-JACIE for transplants, NetCord-FACT for cord blood, and Immune Effector Cells (IEC) standards.
• Accreditation Process: Includes self-assessment, document submission, on-site inspections, and regular re-evaluations every 3-5 years.
• Public Feedback: The Fourth Edition of FACT Common Standards is open for comments until May 11, 2026.

FACT accreditation signals a stem cell bank's commitment to maintaining high standards, ensuring families can trust their stored cells are safe and ready for potential treatments and benefits.

What is FACT and Why It Matters in Cellular Therapy

What FACT Accreditation Means

FACT accreditation sets a high bar for quality across the entire cellular therapy process. Unlike basic regulatory compliance, these standards require facilities to actively oversee both clinical and laboratory practices - not just focus on the end product.

The accreditation relies on detailed benchmarks developed by global experts. These standards are based on published research and widely accepted scientific principles, ensuring they stay aligned with the latest advancements in the field. As of May 2026, 339 organizations worldwide have achieved FACT accreditation, highlighting its broad acceptance across various healthcare environments.

FACT offers several types of specialized standards to address different areas of cellular therapy:

• FACT-JACIE Hematopoietic Standards: Cover bone marrow, peripheral blood, and umbilical cord stem cells used in transplantation.
• NetCord-FACT Cord Blood Standards: Focus on all aspects of cord blood collection, banking, and release.
• Immune Effector Cells (IEC) Standards: Address emerging therapies like CAR T-cells and therapeutic vaccines.
• Common Standards: Provide foundational guidelines for any cell source or application, including non-hematopoietic cells.

Examples of FACT accreditation in action include the Cleveland Cord Blood Center in Ohio, which holds NetCord-FACT accreditation for unrelated cord blood units; the Abu Dhabi Stem Cells Center in the UAE, accredited for FACT-JACIE Hematopoietic Cellular Therapy, covering both minimal and more advanced cell processing; and Akron Children’s Hospital, recognized for Hematopoietic Progenitor Cell Transplantation and Immune Effector Cellular Therapy, particularly for pediatric autologous transplants.

This comprehensive framework underscores the importance of accreditation in maintaining quality and safety, particularly for stem cell banks.

Why Stem Cell Banks Need Accreditation

Accreditation plays a critical role in ensuring consistent quality and safety in the global cellular therapy landscape. Since cellular therapy often involves international collaboration - where a patient’s best donor match may be located in another country - standardized quality requirements are crucial for seamless patient care and regulatory approval across borders.

"FACT Accreditation signals that a cellular therapy program meets FACT Standards and is committed to ongoing quality improvement, reducing variability in care and strengthening trust among patients, providers, and payers." – FACT

For newborn stem cell banking, the NetCord-FACT International Standards (currently in their Eighth Edition, Version 8.2) ensure that cord blood units meet the highest quality benchmarks, whether they are stored for public vs private cord blood banking. These standards emphasize rigorous medical and laboratory practices at every stage, ensuring that cord blood units are viable for lifesaving treatments.

How FACT Works with Global Standards

FACT-JACIE and NetCord-FACT Partnerships

FACT works alongside prominent organizations to develop international standards, ensuring consistent requirements across countries. The FACT-JACIE partnership brings together the Joint Accreditation Committee of ISCT (International Society for Cell & Gene Therapy) and EBMT (European Society for Blood and Marrow Transplantation). Together, they’ve released the Ninth Edition of the International Standards for Hematopoietic Cellular Therapy, which covers procedures for bone marrow, peripheral blood, and umbilical cord stem cell transplants.

Meanwhile, the NetCord-FACT partnership focuses exclusively on cord blood banking. Their collaborative standards, now in the Eighth Edition (Version 8.2), provide comprehensive guidelines for every stage of cord blood collection, banking, and release.

"Cellular therapy is a global effort, as the best donor is often in another country, and harmonized requirements promote patient access and product approvals." – FACT

These standards are developed by international committees made up of clinicians, scientists, technologists, and quality experts. The process also includes public feedback; for instance, the Fourth Edition of the FACT Common Standards for Cellular Therapies is currently open for public review.

By working together, these partnerships not only simplify the creation of standards but also bolster consistency in cellular therapy practices worldwide. This unified approach ensures a reliable framework for quality and smooth cross-border cooperation, which benefits stem cell banks in numerous ways. For many families, understanding these standards helps answer the question, is cord blood banking worth it?

How Global Standards Benefit Stem Cell Banks

Harmonized international standards create a transparent and reliable framework for operations across different countries. When stem cell banks in the U.S. adhere to the same rigorous protocols as their counterparts abroad, the exchange of cellular products becomes much more efficient - especially critical when patients urgently need them.

Standardized guidelines ensure that a cord blood unit collected and stored in one country meets the same quality criteria as one stored elsewhere. This alignment helps with regulatory approvals and reduces inconsistencies in care. Physicians can confidently rely on the quality of cellular therapy products, while the detailed protocols - covering everything from collection to storage and release - enable facilities to detect and address potential quality issues early, ensuring consistent practices worldwide.

The FACT Accreditation Process

Application and Initial Review

To begin the FACT accreditation journey, facilities must first determine which specific standards apply to their operations. For cord blood banks, this means adhering to the NetCord-FACT International Standards for Cord Blood Collection, Banking, and Release for Administration, now in its Eighth Edition, Version 8.2. The accompanying Accreditation Manual provides detailed guidance on meeting these standards.

The process kicks off with a Self-Assessment Tool, which helps facilities evaluate their compliance with FACT requirements. This internal review highlights areas needing improvement before the formal evaluation begins. Facilities are then required to submit a range of detailed documents, including:

• An Applicant Response Template
• Facility Site Grids that outline clinical, collection, and processing locations
• Personnel Lists and Educational Activities Forms
• Descriptions of critical electronic record systems

These submissions establish the scope for the upcoming inspection and demonstrate the facility’s preparedness. Once all documents are reviewed, the process moves to the next phase: the on-site evaluation.

On-Site Inspection and Standards Review

During the on-site visit, a team of FACT-trained professionals - often clinicians, scientists, and technologists with cellular therapy expertise - conducts a thorough review. This team ensures that the facility’s laboratory and clinical practices align with FACT standards. Inspectors also engage with faculty, staff, and administrators to address any questions stemming from the facility’s self-assessment.

The inspection includes observing procedures across the care continuum, from collection to product release. At the end of the visit, an exit interview provides a summary of initial findings. Later, a written report highlights areas of strength, identifies weaknesses, and offers accreditation recommendations. This peer-driven approach ensures feedback is practical and rooted in a deep understanding of the challenges faced by cellular therapy facilities.

Maintaining Accreditation Over Time

Accreditation is not a one-time achievement - facilities must undergo regular reviews every three to five years to retain their status. These periodic evaluations build on the foundation established during the initial accreditation process, ensuring ongoing compliance and quality.

In addition to these formal cycles, facilities are subject to continuous monitoring. This includes annual reporting, which may involve submitting performance metrics, financial updates, and planning documents. Facilities must also report substantive changes whenever significant updates occur in their program’s scope, standards, or practices.

Keeping up with new standards is critical. For instance, facilities are expected to adopt new editions as they are released. Currently, the Fourth Edition of the Common Standards for Cellular Therapies is open for public comment until May 11, 2026. The importance of ongoing compliance is clear - during the 2022-2023 period, 5,744 institutions were reaffirmed, while 783 faced warnings, probation, or termination. This underscores the need for proactive quality management and a constant focus on meeting evolving standards.

Benefits of FACT Accreditation for Stem Cell Banks

Quality Control and Patient Safety

FACT accreditation ensures stem cell banks operate with strict oversight, applying rigorous controls to every phase of their clinical and laboratory processes. These standards are built on solid, evidence-based practices, creating clear benchmarks for all aspects of cord blood banking.

In the case of cord blood banking, FACT standards cover every critical step - collection, processing, storage, and release - ensuring a robust safety framework.

"The major objective of the NetCord-FACT International Standards for Cord Blood Collection, Banking, and Release for Administration is to promote quality medical and laboratory practices throughout all phases of cord blood banking to achieve consistently high-quality cord blood units available to patients for lifesaving treatments."

• NetCord-FACT

To achieve accreditation, facilities must align these standards with their policies and procedures, addressing any gaps before approval is granted. This emphasis on quality not only ensures safety but also fosters trust with clients - a crucial element in this field.

Building Client Trust and Confidence

Families looking to bank their newborn's stem cells need assurance that their chosen facility meets the highest standards. FACT accreditation provides that assurance by confirming compliance with globally recognized benchmarks. On-site inspections add another layer of credibility, as experts directly observe operations, interview staff, and review key documentation, rather than relying on self-reported data.

"FACT Standards are the only standards that emphasize the clinical use of cellular therapy products collected and processed under rigorous controls."

• Foundation for the Accreditation of Cellular Therapy

At Americord Registry, FACT accreditation is central to our commitment to providing transparent and dependable services. This focus ensures that stored stem cells are prepared for real medical applications, not just storage. Additionally, the standards are shaped through public feedback and legal review, making them a globally accepted framework. Families can trust that their facility meets the same stringent criteria applied to top-tier cellular therapy programs worldwide.

The accreditation process itself, which includes application, inspection, and continuous monitoring, highlights a facility’s dedication to quality. Successfully maintaining accreditation over time demonstrates an ongoing commitment to meeting the latest standards in cellular therapy.

How Americord Registry Aligns with FACT Standards

Advanced Processing and Transparency Practices

Americord Registry ensures stem cell quality by adhering to FACT's 72-hour processing window, which is crucial for maintaining cell viability from collection through storage. This timeframe strikes a balance between logistical needs and preserving the therapeutic potential of stem cells for future medical use.

The company’s processing methods align closely with FACT's clinical standards. Through its Cord Blood 2.0™ process, based on the Rubenstein method, Americord isolates higher stem cell yields from cord blood units, ensuring maximum potential for treatments. For cord and placental tissue, the CryoMaxx™ method uses minimal handling to maintain the tissue's natural properties, reflecting FACT's emphasis on preserving therapeutic quality.

Americord also prioritizes transparency, meeting FACT's traceability standards by providing families with Certificates of Storage. These certificates include key details like total nucleated cell (TNC) count and collection volume, giving families concrete data about their stored units. Additionally, Americord’s pioneering role as the first private biobank to offer exosome banking aligns with FACT’s recognition of advancements in regenerative therapies. The use of FDA-approved 5-compartment storage bags for cord blood further supports future treatment flexibility, adhering to FACT's focus on clinical readiness and innovation.

Safety and Compliance for Families

Americord pairs its advanced processing methods with a strong focus on safety and compliance, ensuring families’ investments are well-protected. The company boasts a 100% success rate for the 14 cord blood units it has released for autologous transplants, a testament to its rigorous quality controls and the clinical viability of its products. This achievement reflects FACT's guiding principle that high standards in collection, processing, and storage lead to reliable, lifesaving treatments.

To reinforce its commitment to quality, Americord offers a $110,000 Cord Blood Quality Guarantee, one of the most robust guarantees in the industry. This financial assurance demonstrates confidence in their ability to meet the same stringent controls required of FACT-accredited facilities, which undergo thorough inspections every three years. By providing this guarantee, Americord gives families peace of mind that their investment meets professional-grade standards, far exceeding basic storage requirements. This dedication to safety and quality aligns with the global focus on patient care and excellence that FACT accreditation represents.

Conclusion

FACT accreditation sets the standard for stem cell banking worldwide, ensuring that cellular therapy products are collected and processed under strict quality controls. Since its establishment in 1995, FACT has played a crucial role in maintaining high standards in a field where consistency is vital for meeting international requirements for lifesaving treatments. This rigorous approach helps families make informed decisions about choosing banks that prioritize both safety and clinical preparedness.

For families considering where to store their newborn's stem cells, these standards highlight what truly matters. FACT-accredited banks demonstrate a clear focus on clinical readiness, extending beyond simple storage. The guidelines, crafted by international teams of clinicians, scientists, and regulatory experts, rely on published research and established scientific principles.

As FACT's Fourth Edition remains open for feedback until May 11, 2026, its ongoing updates reflect the rapid progress in regenerative medicine while maintaining cutting-edge practices. This commitment to quality and safety reinforces FACT accreditation as the gold standard in stem cell banking.

When exploring stem cell banking options, families should prioritize services that emphasize transparency, advanced processing methods, and strict quality controls. These elements ensure that stored stem cells retain their therapeutic value when needed most.

FAQs

Is FACT accreditation required by law?

No, FACT accreditation is not a legal requirement. It is a voluntary program designed to establish minimum guidelines for cellular therapy practices. While adhering to FACT standards isn't enforced by law, it plays a key role in promoting quality and safety in stem cell banking and related services.

How can I verify a stem cell bank is FACT-accredited?

To verify if a stem cell bank holds FACT accreditation, visit the official FACT website and review their list of accredited organizations. Alternatively, you can confirm directly with the bank to ensure they have successfully completed the FACT accreditation process. Both methods offer trustworthy ways to confirm accreditation status.

Does FACT accreditation affect whether stored cells can be used in treatment?

FACT accreditation plays a key role in confirming that a cellular therapy program adheres to recognized quality and safety standards. However, it’s important to note that this accreditation alone doesn’t guarantee that stored cells are suitable for treatment. The actual use of these cells depends on other factors, such as clinical eligibility and regulatory approval, which must be evaluated separately.